title: Plasma itraconazole concentrations in patients with neutropenia: advantages of a divided daily dosage regimen.
abstract: A group of 36 patients in the hematology department of Saint-Antoine Hospital, Paris, France, was on chemotherapy. The patients were also given antiacid drugs to prevent gastrointestinal toxicity and itraconazole as prophylaxis against aspergillosis. The antifungal drug was given as 100-mg capsules three times a day shortly after meals. The plasma itraconazole and hydroxyitraconazole concentrations were measured by high-performance liquid chromatography at steady state. Of 36 patients, 29 (81%) had adequate plasma itraconazole concentrations (> or = 250 ng/ml) after 8 +/- 2 days. The 7 patients with low plasma itraconazole concentrations were given 200 mg three times a day. Of the 36 patients, 34 (94%) had effective plasma concentrations within 2 weeks of the beginning of treatment. The two remaining patients were lost to follow-up. The proposed itraconazole regimen provides effective prophylaxis against aspergillosis and represents a substantial economic advantage over a single daily dose of 400 to 600 mg. The marked intrapatient and interpatient variations in plasma itraconazole indicate the need for regular therapeutic drug monitoring to ensure effective plasma itraconazole concentrations in all neutropenic patients.
authors.affiliation: Department of Pharmacology, Saint-Antoine Hospital, Paris, France.
authors.forename: J M
authors.initials: JM
authors.lastname: Poirier
authors.forename: S
authors.initials: S
authors.lastname: Hardy
authors.forename: F
authors.initials: F
authors.lastname: Isnard
authors.forename: P
authors.initials: P
authors.lastname: Tilleul
authors.forename: J
authors.initials: J
authors.lastname: Weissenburger
authors.forename: G
authors.initials: G
authors.lastname: Cheymol
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000097:blood; D000970:Antineoplastic Agents / Q000009:adverse effects; D016903:Drug Monitoring; D006801:Humans; D017964:Itraconazole / Q000008:administration & dosage* / Q000097:blood; D007938:Leukemia / Q000188:drug therapy; D008223:Lymphoma / Q000188:drug therapy; D008875:Middle Aged; D009181:Mycoses / Q000209:etiology / Q000517:prevention & control*; D009503:Neutropenia / Q000139:chemically induced / Q000150:complications / Q000378:metabolism*
chemical_list: D000935:Antifungal Agents; D000970:Antineoplastic Agents; D017964:Itraconazole